• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾移植后免疫抑制的监测。

Monitoring immunosuppression following renal transplantation.

作者信息

Giorgi J V, Cosimi A B, Colvin R B, Goldstein G, Delmonico F L, Russell P S

出版信息

Diagn Immunol. 1983;1(3):174-8.

PMID:6388969
Abstract

Renal allograft recipients were given azathioprine and prednisone for immunosuppression following transplantation. In addition, pulses of steroids or courses of treatment with antithymocyte globulin (ATG) or PAN.OKT3 were employed to combat acute rejection episodes. Our results support the concept that ATG and PAN.OKT3 are useful in the treatment of acute kidney allograft rejection. In our experience, ATG often reversed acute kidney allograft rejection episodes and then provided relatively long-lasting immunosuppression with stable graft function. In contrast, PAN.OKT3 was more effective in reversing acute rejection, but subsequent rejection episodes occurred more frequently. In patients treated with PAN.OKT3, cells reacting with OKT3, OKT4 and OKT8 were removed from the circulation within minutes following the initial treatment, and the levels of these cells remained dramatically depressed during the first few days of treatment. Subsequently, peripheral blood cells which reacted with OKT4 or OKT8, but not OKT3, could be detected in most patients, even though treatment continued and excess circulating PAN.-OKT3 was present. Experiments in which these cells were cultured for 24 or 72 hr indicated that antigenic modulation by OKT3 had occurred in vivo. These results raise interesting questions about the mode of action of PAN.OKT3, and suggest that the combination of PAN.OKT3 with an agent which can establish long-lasting immunosuppression may be more effective than either agent given alone.

摘要

肾移植受者在移植后接受硫唑嘌呤和泼尼松进行免疫抑制。此外,还使用了类固醇脉冲疗法或抗胸腺细胞球蛋白(ATG)或OKT3单抗的疗程来对抗急性排斥反应。我们的结果支持ATG和OKT3单抗在治疗急性肾移植排斥反应中有用的概念。根据我们的经验,ATG常常能逆转急性肾移植排斥反应,然后提供相对持久的免疫抑制,使移植肾功能稳定。相比之下,OKT3单抗在逆转急性排斥反应方面更有效,但随后的排斥反应更频繁地发生。在用OKT3单抗治疗的患者中,与OKT3、OKT4和OKT8反应的细胞在初始治疗后几分钟内就从循环中清除,并且在治疗的头几天这些细胞的水平仍显著降低。随后,在大多数患者中可以检测到与OKT4或OKT8反应但不与OKT3反应的外周血细胞,即使治疗仍在继续且循环中有过量的OKT3单抗。将这些细胞培养24或72小时的实验表明,OKT3在体内发生了抗原调节。这些结果提出了关于OKT3单抗作用方式的有趣问题,并表明OKT3单抗与能建立持久免疫抑制的药物联合使用可能比单独使用任何一种药物更有效。

相似文献

1
Monitoring immunosuppression following renal transplantation.肾移植后免疫抑制的监测。
Diagn Immunol. 1983;1(3):174-8.
2
A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.心脏移植中基于鼠单克隆CD-3(OKT3)抗体和基于马抗胸腺细胞球蛋白的排斥反应预防措施的前瞻性比较。使用OKT3可降低排斥反应并减少皮质类固醇的使用。
Transplantation. 1989 Apr;47(4):599-605.
3
Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.心脏移植中基于OKT3与马抗胸腺细胞球蛋白的免疫抑制预防的前瞻性随机试验。
J Heart Transplant. 1990 May-Jun;9(3 Pt 2):306-15.
4
Comparison of Minnesota antilymphocyte globulin and OKT3 for induction of immunosuppression in renal transplant patients.明尼苏达抗淋巴细胞球蛋白与OKT3用于诱导肾移植患者免疫抑制的比较。
Transplant Proc. 1989 Feb;21(1 Pt 2):1738-40.
5
FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.FK506治疗难治性肾移植排斥反应:来自肝移植的经验教训。
Clin Transplant. 1996 Aug;10(4):323-32.
6
Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.四联免疫抑制:OKT3与明尼苏达抗淋巴细胞球蛋白的比较。
Am J Kidney Dis. 1989 Nov;14(5 Suppl 2):10-3.
7
The OKT3 immunosuppressive effect. In situ antigenic modulation of human graft-infiltrating T cells.OKT3免疫抑制作用。人移植浸润性T细胞的原位抗原调节。
Transplantation. 1990 Jan;49(1):156-60.
8
[In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].[OKT3单克隆抗体在同种异体肾移植受者中的体内应用]
Nephrologie. 1987;8(3):95-8.
9
One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.一个中心使用抗胸腺细胞球蛋白治疗肾移植急性排斥反应的经验。
Transplant Proc. 2008 Jan-Feb;40(1):123-5. doi: 10.1016/j.transproceed.2007.12.008.
10
A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.一项随机前瞻性研究,比较低剂量OKT3与低剂量抗胸腺细胞球蛋白用于治疗肾移植受者急性类固醇抵抗性排斥反应发作的疗效。
Transpl Int. 1998;11(3):231-6. doi: 10.1007/s001470050133.

引用本文的文献

1
Muromonab CD3. A review of its pharmacology and therapeutic potential.莫罗单抗-CD3。其药理学与治疗潜力综述。
Drugs. 1989 Jun;37(6):871-99. doi: 10.2165/00003495-198937060-00004.
2
OKT3 prophylaxis in liver transplantation.肝移植中OKT3的预防应用
Dig Dis Sci. 1991 Oct;36(10):1418-26. doi: 10.1007/BF01296809.